HGF and breast carcinoma: Using the breast cancer cell line MDA-MB-453 and GBM cell line U-373, treatment with cMET receptor ligand hepatocyte growth factor/scatter factor was shown to impart resistance to doxorubicin/adriamycin and cisplatin [66, 67].